Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





Reported Tuberculosis in the United States, 2017										Related Pages
										Return to Main Menu
Table 51. Tuberculosis Cases and Percentages, by Completion of Tuberculosis Therapy (COT): Reporting Areas, 20151
Table 51. Tuberculosis Cases and Percentages, by Completion of Tuberculosis Therapy (COT): Reporting Areas, 2015
Reporting Area
Total Cases
Therapy ≤1 year indicated2,3,4
Therapy >1 year indicated3,5No.
COT ≤1 year(%)
COT(%)
No.
COT(%)**United States**
**9,547**
**7,860**
**(89.5)**
**(95.8)**
**519**
**(90.2)**Alabama
119
98
(85.7)
(95.9)
6
(100.0)Alaska
68
59
(93.2)
(100.0)
5
(100.0)Arizona
198
151
(92.1)
(98.0)
9
(88.9)Arkansas
90
79
(84.8)
(96.2)
4
(100.0)California
2,131
1,764
(88.2)
(95.4)
105
(87.6)Colorado
73
61
(95.1)
(96.7)
6
(100.0)Connecticut
70
56
(94.6)
(100.0)
6
(100.0)Delaware
22
18
(88.9)
(100.0)
2
(100.0)District of Columbia
33
24
(87.5)
(95.8)
2
(100.0)Florida
602
496
(95.6)
(98.4)
34
(88.2)Georgia
320
270
(90.4)
(97.8)
17
(100.0)Hawaii
127
113
(95.6)
(99.1)
6
(100.0)Idaho
11
9
(100.0)
(100.0)
1
(100.0)Illinois
343
289
(94.5)
(98.6)
15
(100.0)Indiana
116
101
(94.1)
(96.0)
5
(100.0)Iowa
38
34
(85.3)
(91.2)
1
(100.0)Kansas
36
32
(93.8)
(96.9)
3
(66.7)Kentucky
67
53
(94.3)
(100.0)
7
(100.0)Louisiana
119
107
(65.4)
(72.9)
4
(75.0)Maine
18
15
(100.0)
(100.0)
1
(100.0)Maryland
176
141
(90.8)
(98.6)
14
(92.9)Massachusetts
192
151
(88.7)
(97.4)
15
(93.3)Michigan
131
112
(95.5)
(99.1)
4
(100.0)Minnesota
150
125
(95.2)
(97.6)
15
(93.3)Mississippi
73
55
(89.1)
(96.4)
3
(100.0)Missouri
92
77
(81.8)
(88.3)
5
(80.0)Montana
9
7
(100.0)
(100.0)
1
(100.0)Nebraska
33
27
(37.0)
(37.0)
3
(0.0)Nevada
85
71
(94.4)
(98.6)
3
(100.0)New Hampshire
13
7
(100.0)
(100.0)
3
(100.0)New Jersey
326
254
(90.9)
(97.2)
20
(85.0)New Mexico
47
29
(93.1)
(96.6)
2
(100.0)New York State6
188
149
(94.0)
(97.3)
12
(83.3)New York City
575
489
(94.1)
(98.0)
35
(97.1)North Carolina
199
162
(92.6)
(99.4)
12
(100.0)North Dakota
9
7
(85.7)
(85.7)
0
...Ohio
143
116
(83.6)
(93.1)
6
(100.0)Oklahoma
67
59
(88.1)
(96.6)
0
...Oregon
76
64
(89.1)
(95.3)
5
(100.0)Pennsylvania
200
165
(80.6)
(93.3)
5
(100.0)Rhode Island
30
23
(100.0)
(100.0)
2
(100.0)South Carolina
104
86
(91.9)
(94.2)
4
(100.0)South Dakota
17
14
(50.0)
(78.6)
0
...Tennessee
131
106
(95.3)
(96.2)
10
(90.0)Texas
1,334
1,089
(87.5)
(94.5)
70
(82.9)Utah
37
31
(93.5)
(96.8)
5
(100.0)Vermont
7
7
(100.0)
(100.0)
0
...Virginia
212
180
(92.2)
(97.2)
10
(100.0)Washington
207
162
(74.1)
(90.1)
13
(76.9)West Virginia
10
6
(83.3)
(100.0)
1
(0.0)Wisconsin
69
58
(86.2)
(100.0)
2
(50.0)Wyoming
4
2
(100.0)
(100.0)
0
...American Samoa7
4
4
(0.0)
(0.0)
0
...Fed. States of Micronesia7
103
93
(90.3)
(91.4)
2
(50.0)Guam7
76
66
(60.6)
(62.1)
3
(66.7)Marshall Islands7
136
118
(87.3)
(91.5)
2
(100.0)N. Mariana Islands7
27
25
(80.0)
(88.0)
1
(100.0)Puerto Rico7
52
38
(73.7)
(86.8)
2
(100.0)Republic of Palau7
14
11
(90.9)
(90.9)
2
(100.0)U.S. Virgin Islands7
0
...
...
...
...
...1 Most recent year for which data are available.2 Initial isolate susceptible to rifampin (n = 5,915) or susceptibility unknown (n = 74); culture negative (n = 1,566); culture status unknown (n = 305).3 Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of Columbia).4 Therapy ≤1 year indicated in persons alive at diagnosis with an initial regimen of one or more drugs prescribed, who did not die within one year of initiating therapy. Excludes persons with initial isolate rifampin resistant, or patient with bone and joint disease, meningeal disease or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and those who moved out of the country within one year of initiating treatment.5 Initial isolate rifampin resistant, or patient with meningeal disease or bone and joint disease, or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and those who did not move out of the country or die during treatment.6 Excludes New York City.7 Not included in U.S. totals.**Note:** Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
See Technical Notes for description of completion of therapy calculation.
							
					
						Page last reviewed:  October 22, 2018					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue